Skip to main content
Fig. 6 | BMC Bioinformatics

Fig. 6

From: In silico trial to test COVID-19 candidate vaccines: a case study with UISS platform

Fig. 6

In silico trial of 47D11 to predict preventive efficacy. The overall prediction dynamics of LEP at the injection time of 47D11 mAb (day 1) at a concentration of 10 ng/ml after different SARS-CoV-2 challenge in time (a–f) is depicted. Specifically, one can observe the exposures at virus particles at day 7 (a), day 14 (b), month 1 (c), month 3 (d), month 6 (e) and after 1 year (f). Solid lines refer to the no-treated digital patient while dashed lines refer to mAb treated one. Blue lines depict actively infected LEP while red lines represent LEP to show the CPE. Panel A highlights that if a patient enters in contact with the virus just after 7 days post vaccination, he is fully protected from the infection (SARS-CoV-2 actively infected values of LEP are low). This is also true if a potential subject is being infected after 2 weeks (b), 1 month (c) or 3 months (d) after vaccination. Oppositely, in e (subject infected after 6 months) and f (subject infected after 1 year) mAb vaccination is practically ineffective in protecting the onset of the disease

Back to article page